摘要
阿尔茨海默氏病(AD)是一种神经退行性疾病,主要的危险因素是年龄,因为它的发病率在60岁以后急剧增加。它是最常见的痴呆症,并伴有记忆力减退和认知障碍。虽然阿尔茨海默氏病是一个多世纪前发现的,但是唯一被批准的药物是由美国食品和药物管理局用于处理四胆碱酯酶抑制剂美金刚。然而,这些药物在治疗阿尔茨海默氏病上并不完全有效,因此,随着患者对有效治疗方法和生活水平提高的希望,为治疗阿尔茨海默病持续不断搜索新方法。最新证据表明,由于其抗神经炎症的影响,抗生素米诺环素可用于阿尔茨海默氏病的一个潜在治疗药物的希望。米诺环素是一种四环素衍生物的抗炎特性相结合,可通过血脑屏障的保护性能和工作限制炎症和氧化应激。一些研究已经建立大脑炎症标记受阿尔茨海默病痛苦的患者上,包括细胞因子/趋化因子在受损区域的解释水平升高。细胞因子已增加tau蛋白磷酸化有关,突触体素水平降低,在阿尔茨海默病.患者上建立细胞和突触改变建立自己的角色。因此,药理学方法,针对阿尔茨海默病允许新的抗炎药物如米诺环素的发现和发展。考虑到这些事实,本文将讨论米诺环素神经保护作用下的抗炎机制,作为对阿尔茨海默病.的一种新的治疗方法。
关键词: 阿尔茨海默病,阿尔茨海默病治疗,细胞因子,米诺环素,神经炎症,小胶质细胞的激活
Current Alzheimer Research
Title:The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Volume: 13 Issue: 12
Author(s): J. Budni, M. L. Garcez, J. de Medeiros, E. Cassaro, T. Bellettini-Santos, F. Mina, J. Quevedo
Affiliation:
关键词: 阿尔茨海默病,阿尔茨海默病治疗,细胞因子,米诺环素,神经炎症,小胶质细胞的激活
摘要: Alzheimer's disease (AD) is a neurodegenerative disorder where the main risk factor is age, since its incidence increases dramatically after the age of 60. It is the most common form of dementia, and is accompanied by memory loss and cognitive impairment. Although AD was discovered over a century ago, the only drugs approved by the US Food and Drug Administration for use in its treatment are four cholinesterase inhibitors and memantine. However, these drugs are not fully effective in the treatment of AD. Therefore, the incessant search for new methods of treating AD continues, with the hope of improving both the effectiveness of therapies and the quality of life for patients suffering with AD. Current evidence suggests that the antibiotic minocycline could be a potential therapeutic drug for use in the treatment of AD due to its anti-neuroinflammatory effects. Minocycline is a tetracycline derivative that combines an anti-inflammatory property that is capable of crossing the blood brain barrier with neuroprotective properties that work by limiting inflammation and oxidative stress. Several studies have established the presence of inflammatory markers in the brains of patients suffering with AD, including elevated levels of cytokines/chemokines and microgliosis in damaged regions. Cytokines have been associated with increased tau phosphorylation and decreased levels of synaptophysin, establishing their roles in the cytoskeletal and synaptic alterations that take place in AD. Therefore, pharmacological approaches that allow for the discovery and development of new anti-inflammatory agents such as minocycline will be welcomed in the continuing struggle against AD. Considering these facts, this review will discuss the anti-inflammatory mechanisms underlying the neuroprotective effects of minocycline as a novel therapeutic approach for the treatment of AD.
Export Options
About this article
Cite this article as:
J. Budni, M. L. Garcez, J. de Medeiros, E. Cassaro, T. Bellettini-Santos, F. Mina, J. Quevedo , The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160819124206
DOI https://dx.doi.org/10.2174/1567205013666160819124206 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Sleep Apnea and Coronary Heart Disease: From Dusk Till Dawn and Further
Current Respiratory Medicine Reviews Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Implications of Some Selected Flavonoids Towards Alzheimer’s Disease with the Emphasis on Cholinesterase Inhibition and their Bioproduction by Metabolic Engineering
Current Pharmaceutical Biotechnology Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Plasma Gelsolin: Function, Prognostic Value, and Potential Therapeutic Use
Current Protein & Peptide Science Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors
Current Alzheimer Research Novel Pyrimidine based Semicarbazones: Confirmation of Four Binding Site Pharmacophoric Model Hypothesis for Antiepileptic Activity
Central Nervous System Agents in Medicinal Chemistry MicroRNA Dysregulation in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes
Current Clinical Pharmacology In Silico Search and Toxicology Prediction of Novel Potential β-Secretase Inhibitors in Alzheimers Disease
Current Bioactive Compounds